GNLX Stock Analysis: Buy, Sell, or Hold?
GNLX - Genelux Corporation Common Stock
$2.66
-0.08 (-2.92%)
▼
5d:
-7.32%
30d:
-38.71%
90d:
-65.45%
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Apr 06, 2026
Get Alerted When GNLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GNLX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GNLX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GNLX is currently trading at $2.66, which is considered slightly low relative to its 30-day fair value range of $2.51 to $3.85.
Technical Outlook: Technically, GNLX is in a downtrend. Immediate support is located at $2.55, while resistance sits at $3.07.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.33 (+626.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GNLX is in a downtrend. Immediate support is located at $2.55, while resistance sits at $3.07.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.33 (+626.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$2.51 -
$3.85
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 626.8% below Wall St target ($19.33)
- CAUTION: Recommendation downgraded due to -7.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.51 -
$3.85
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.63
(23.7%)
Support & Resistance Levels
Support Level
$2.55
Resistance Level
$3.07
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.84
Wall Street Target
$19.33
(+626.8%)
Revenue Growth (YoY)
-95.3%
Last updated: February 02, 2026 8:36 AM ET
Data refreshes hourly during market hours. Next update: 9:36 AM
Data refreshes hourly during market hours. Next update: 9:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GNLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 52 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 60 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$42 | 53 HOLD |
